From: Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Patientnumber | MRI response | pHER2 reduction | pERK1 reduction | MRI-pHER2 correlation | MRI-pERK1 correlation |
---|---|---|---|---|---|
1 | No Change* | NA | No | NA | NA |
2 | PR | No | No | No | No |
3 | PR | Yes | Yes | Yes | Yes |
4 | PR | Yes | No | Yes | No |
5 | No change* | NA | NA | NA | NA |
6 | No change* | NA | NA | NA | NA |
7 | No change* | No | No | NA | NA |
8 | PR | No | No | No | No |
9 | PR | Yes | No | Yes | No |
10 | PR | Yes | No | Yes | No |
11 | PR | NA | NA | No | No |
12 | No change* | NA | No | NA | NA |
13 | No change* | NA | NA | NA | NA |
14 | SD | Yes | No | No | No |
15 | No change* | Yes | Yes | NA | NA |
16 | SD | No | No | No | No |
17 | PR | Yes | Yes | Yes | Yes |
18 | PR | Yes | No | Yes | No |
19 | No change* | Yes | Yes | NA | NA |
20 | SD | No | No | No | No |